GH Research PLC (NASDAQ:GHRS - Get Free Report)'s share price shot up 3.8% during trading on Wednesday . The company traded as high as $9.60 and last traded at $9.50. 9,127 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 79,000 shares. The stock had previously closed at $9.15.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a report on Wednesday, September 4th.
Check Out Our Latest Stock Analysis on GHRS
GH Research Trading Up 1.4 %
The business has a fifty day simple moving average of $7.72 and a 200 day simple moving average of $10.40.
GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. Equities research analysts expect that GH Research PLC will post -0.85 EPS for the current fiscal year.
Institutional Trading of GH Research
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. grew its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 11.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,251,714 shares of the company's stock after purchasing an additional 664,381 shares during the period. RA Capital Management L.P. owned approximately 12.02% of GH Research worth $66,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 56.90% of the company's stock.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
